Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Precipio, Inc.PRPO · Entity 7207 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Precipio, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectWythburn Associates, Ltd, 94% owned jointly by reporting person and spouse | 3,000 |
Reported balance
After 2026-05-21 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-21 · Sale · Disposed 900 · Balance 3,000 F1: Shares disposed in open market transactions by Wythburn Associates, Ltd, which is 94% owned jointly by the reporting person and their spouse. The reporting person disclaims beneficial ownership of the securities except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 8,142 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,142 |
| Common StockSEC Table I · non-derivative | IndirectRoth IRA for the benefit of Richard A Sandberg | 25,000 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares disposed in open market transactions by Wythburn Associates, Ltd, which is 94% owned jointly by the reporting person and their spouse. The reporting person disclaims beneficial ownership of the securities except to the extent of their pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Oxford Immunotec Global PLC
Report date March 08, 2021 · Filed March 12, 2021
Section 16 reporting ended · disclosed 2021-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Disposition to issuer · Disposed 4,081 · Balance 0 F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.86 · Expires 2024-06-12 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2025-06-09 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-06-28 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Disposition to issuer · Disposed 6,107 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.49 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.44 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-08 · Disposition to issuer · Disposed 9,494 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2021 Filed Mar 12, 2021 21:36 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.51 Strike: $14.49 | $56,002.07 |
DisclosureSEC source: 0001140361-21-008349 · form4.xml · derivative · entry 6 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2028-06-19 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:36 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.54 Strike: $14.46 | $56,225.78 |
DisclosureSEC source: 0001140361-21-008349 · form4.xml · derivative · entry 5 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2027-06-06 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:36 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,107 | $13.35 Strike: $8.65 | $81,528.45 |
DisclosureSEC source: 0001140361-21-008349 · form4.xml · derivative · entry 4 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,107 shares Expires 2026-06-28 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:36 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $7.83 Strike: $14.17 | $58,388.31 |
DisclosureSEC source: 0001140361-21-008349 · form4.xml · derivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2025-06-09 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:36 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,457 | $5.14 Strike: $16.86 | $38,328.98 |
DisclosureSEC source: 0001140361-21-008349 · form4.xml · derivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,457 shares Expires 2024-06-12 F3 · price: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2 · derivative.exercise_date: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. Read SEC document |
| March 08, 2021 Filed Mar 12, 2021 21:36 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Disposition to issuerOrdinary Shares | 4,081 | $22.00 | $89,782.00 |
DisclosureSEC source: 0001140361-21-008349 · form4.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:32 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-21-000966 · tm211613-6_4seq1.xml · derivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-01-04 F2 · price: Issued pursuant to the Issuer's Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:33 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 1,250 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001104659-20-081249 · tm2024163d8_4.xml · derivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires 2030-07-02 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:03 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantShare Option (Right to Buy) · Derivative | 9,494 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001437749-20-013982 · rdgdoc.xml · derivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,494 Underlying: Ordinary Shares · 9,494 shares Expires 2030-06-24 F1 · security: Options granted under Issuer's 2013 Share Incentive Plan. F2 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the underlying shares on the earlier of the first anniversary of the date of grant or the date of the first annual general meeting of the shareholders held after the date of grant. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:03 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantOrdinary Shares | 4,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-013982 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:22 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-20-005501 · tm205425-3_4.xml · derivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-01-16 F2 · price: Issued pursuant to the Company Equity Incentive Plan in consideration for the Reporting Person's service as a director of the Issuer F1 · derivative.exercise_date: The options shall vest in twelve equal monthly installments beginning on the one month anniversary of the date of the issuance Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 22:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantEmployee Stock Option (right to buy) · Derivative | 5,171 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-19-069958 · tm1924505d2_4.xml · derivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,171 Underlying: Common Stock · 5,171 shares Expires 2029-12-03 F1 · kind: On December 3, 2019 (the "Effective Date"), Mr. Richard Sandberg (the "Reporting Person") was appointed to the Board of Directors of Precipio, Inc. (the "Company"). In connection with the Reporting Person's appointment and pursuant to the Company's 2017 Stock Option and Incentive Plan, the Company issued to the Reporting Person and option to purchase 2,000 and 5,000 shares, respectively (the "Options"), at an exercise price of $2.18 (the closing price of the Company's common stock on the Effective Date). F3 · derivative.exercise_date: The Option vests in thirty-six equal monthly installments beginning on the Effective Date. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 22:10 UTC | Precipio, Inc. PRPO · Entity 7207 | GrantEmployee Stock Option (right to buy) · Derivative | 2,069 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001104659-19-069958 · tm1924505d2_4.xml · derivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,069 Underlying: Common Stock · 2,069 shares Expires 2029-12-03 F1 · kind: On December 3, 2019 (the "Effective Date"), Mr. Richard Sandberg (the "Reporting Person") was appointed to the Board of Directors of Precipio, Inc. (the "Company"). In connection with the Reporting Person's appointment and pursuant to the Company's 2017 Stock Option and Incentive Plan, the Company issued to the Reporting Person and option to purchase 2,000 and 5,000 shares, respectively (the "Options"), at an exercise price of $2.18 (the closing price of the Company's common stock on the Effective Date). F2 · derivative.exercise_date: The Option vests in twelve equal monthly installments beginning on the Effective Date. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:02 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,350 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001437749-19-021587 · rdgdoc.xml · derivative · entry 5 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Ordinary Shares · 1,350 shares Expires 2026-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise from an option granted June 28, 2016, which became fully vested on June 6, 2017. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:02 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,650 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001437749-19-021587 · rdgdoc.xml · derivative · entry 4 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,650 shares Expires 2020-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Exercise from an option granted February 18, 2010, which became fully vested on April 1, 2014. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:02 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $15.60 | $46,800.00 |
DisclosureSEC source: 0001437749-19-021587 · rdgdoc.xml · nonDerivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:02 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 1,350 | $8.65 | $11,677.50 |
DisclosureSEC source: 0001437749-19-021587 · rdgdoc.xml · nonDerivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:02 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 1,650 | $0.09 | $148.50 |
DisclosureSEC source: 0001437749-19-021587 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 23:43 UTC Amendment | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $12.90 | $38,702.70 |
DisclosureSEC source: 0001437749-19-015509 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: The price reported for the sales on August 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $12.925 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. F3 · price: Price amended from the original filing made on 08/05/2019 which reflected a price of $19.9009 to the corrected price of $12.9009. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $19.90 | $59,702.70 |
DisclosureSEC source: 0001437749-19-015473 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: The price reported for the sales on August 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.90 to $12.925 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 20:31 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0001437749-19-012287 · rdgdoc.xml · derivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2029-06-18 F1 · derivative.exercise_date: The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| May 01, 2019 Filed May 3, 2019 20:31 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $16.05 | $48,155.10 |
DisclosureSEC source: 0001437749-19-008716 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: The price reported for the sales on May 1, 2019 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.1150 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 21:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $14.25 | $42,750.90 |
DisclosureSEC source: 0001437749-19-001701 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $15.50 | $46,500.00 |
DisclosureSEC source: 0001437749-18-019297 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $13.15 | $39,450.00 |
DisclosureSEC source: 0001437749-18-014436 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:31 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.49 | $0.00 |
DisclosureSEC source: 0001437749-18-012237 · rdgdoc.xml · derivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2028-06-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001437749-18-008383 · rdgdoc.xml · derivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,650 Underlying: Ordinary Shares · 3,000 shares Expires 2020-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise from an option award granted February 18, 2010, which became fully vested on April 1, 2014. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $12.77 | $38,304.00 |
DisclosureSEC source: 0001437749-18-008383 · rdgdoc.xml · nonDerivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: The price reported for the sales on May 1, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $12.93 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 3,000 | $0.09 | $270.00 |
DisclosureSEC source: 0001437749-18-008383 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 16, 2018 21:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001437749-18-002791 · rdgdoc.xml · derivative · entry 6 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650 Underlying: Ordinary Shares · 2,500 shares Expires 2020-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise from an option award granted February 18, 2010, which became fully vested on April 1, 2014. Read SEC document |
| February 16, 2018 Filed Feb 16, 2018 21:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 2,500 | $12.02 | $30,037.50 |
DisclosureSEC source: 0001437749-18-002791 · rdgdoc.xml · nonDerivative · entry 4 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: The price reported for the sales on February 16, 2018 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.165 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| February 16, 2018 Filed Feb 16, 2018 21:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 2,500 | $0.09 | $225.00 |
DisclosureSEC source: 0001437749-18-002791 · rdgdoc.xml · nonDerivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 21:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 500 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001437749-18-002791 · rdgdoc.xml · derivative · entry 5 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,150 Underlying: Ordinary Shares · 500 shares Expires 2020-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise from an option award granted February 18, 2010, which became fully vested on April 1, 2014. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 21:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 500 | $12.00 | $6,000.00 |
DisclosureSEC source: 0001437749-18-002791 · rdgdoc.xml · nonDerivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 21:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 500 | $0.09 | $45.00 |
DisclosureSEC source: 0001437749-18-002791 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 222 | $0.00 Strike: $0.09 | $0.00 |
DisclosureSEC source: 0001437749-17-018162 · rdgdoc.xml · derivative · entry 5 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Underlying: Ordinary Shares · 222 shares Expires 2020-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Exercise from an option award granted February 18, 2010, which became fully vested on April 1, 2014. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,778 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001437749-17-018162 · rdgdoc.xml · derivative · entry 4 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,778 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise from an option award granted November 7, 2012, which became fully vested on December 31, 2016. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $13.35 | $40,050.00 |
DisclosureSEC source: 0001437749-17-018162 · rdgdoc.xml · nonDerivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: The price reported for the sales on November 1, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.35 to $13.3501 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 222 | $0.09 | $19.98 |
DisclosureSEC source: 0001437749-17-018162 · rdgdoc.xml · nonDerivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 2,778 | $0.81 | $2,250.18 |
DisclosureSEC source: 0001437749-17-018162 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001437749-17-015577 · rdgdoc.xml · derivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,778 Underlying: Ordinary Shares · 3,000 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $15.82 | $47,459.70 |
DisclosureSEC source: 0001437749-17-015577 · rdgdoc.xml · nonDerivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: The price reported for the sales on September 1, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.7601 to $15.9000 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 20:30 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 3,000 | $0.81 | $2,430.00 |
DisclosureSEC source: 0001437749-17-015577 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 20:33 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0001437749-17-010972 · rdgdoc.xml · derivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:42 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GiftOrdinary Shares | 2,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-010485 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| May 10, 2017 Filed May 11, 2017 21:10 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001437749-17-008791 · rdgdoc.xml · derivative · entry 3 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,778 Underlying: Ordinary Shares · 3,000 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016. Read SEC document |
| May 10, 2017 Filed May 11, 2017 21:10 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleOrdinary Shares | 3,000 | $14.40 | $43,200.00 |
DisclosureSEC source: 0001437749-17-008791 · rdgdoc.xml · nonDerivative · entry 2 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,174 Read SEC document |
| May 10, 2017 Filed May 11, 2017 21:10 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | Exercise / conversionOrdinary Shares | 3,000 | $0.81 | $2,430.00 |
DisclosureSEC source: 0001437749-17-008791 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:29 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleORDINARY SHARES | 3,000 | $15.47 | $46,419.90 |
DisclosureSEC source: 0001437749-17-006143 · rdgdoc.xml · nonDerivative · entry 1 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,174 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2016. F2 · price: The price reported for the sales on April 3, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.38 to $15.525 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| November 08, 2016 Filed Nov 9, 2016 21:41 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | SaleORDINARY SHARES | 9,500 | $14.17 | $134,567.50 |
DisclosureSEC source: 0001437749-16-041579 · rdgdoc.xml · nonDerivative · entry 5 SANDBERG RICHARD A · CIK 0001245055 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,174 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.